Expression profile of microRNAs in expressed prostatic secretion of healthy men and patients with IIIA chronic prostatitis/ chronic pelvic pain syndrome
Metrics: PDF 555 views | HTML 832 views | ?
Ye Chen1,*, SuNing Chen2,*, Jian Zhang3,*, YangMin Wang4, Zhengping Jia5, Xin Zhang4, Xiao Han4, Xiuquan Guo4, XiaoDi Sun4, Chen Shao6, Ji Wang7 and Tian Lan4,6
1Department of Anesthesiology and Pain, Lanzhou General Hospital of Lanzhou Command, Lanzhou, China
2Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi’an, China.
3Department of Biochemistry and Molecular Biology and the State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an, China
4Department of Urology, Lanzhou General Hospital of Lanzhou Command, Lanzhou, China
5Key Laboratory of the Plateau of the Environmental Damage Control, Lanzhou General Hospital of Lanzhou Military Command, Lanzhou, China
6Department of Urology, Xiang’an Hospital, University of XiaMen, Xiamen, China
7Laboratory of Cell Death and Cancer Genetics, The University of Minnesota Hormel Institute, Austin, MN, United States
*These authors contributed equally to this work
Tian Lan, email: email@example.com
Ji Wang, email: firstname.lastname@example.org
Keywords: prostate; microRNAs; chronic prostatitis/chronic pelvic pain syndrome; mir-21; high-throughput sequencing
Received: August 23, 2017 Accepted: November 26, 2017 Published: January 06, 2018
The current study aimed to identify a comprehensive expression-profile of microRNAs (miRNAs) in expressed prostatic secretion (EPS) collected from healthy men and patients with CP/CPPS (Chronic prostatitis/Chronic pelvic pain syndrome). After clinical screening of 382 participants, 60 healthy men and 59 IIIA CP/CPPS patients with significant pelvic-pain were included into this study from March 2012 to December 2014. High-throughput sequencing was employed to identify characteristic expression-profile of EPS-miRNAs. QRT-PCR was further performed to confirm elevated levels of differential EPS-miRNAs. Finally, candidate EPS-miRNAs were measured traceably in 21 follow-up patients and their classify-accuracy on IIIA CP/CPPS were analyzed by ROC (receiver operating characteristic) curve. In discovery-phage, 41 and 43 predominant EPS-miRNAs were found in pooled EPS-sample from 40 healthy men and 39 IIIA CP/CPPS patients, respectively. Furthermore, 22 abundant EPS-miRNAs were up-regulated with ≥ 2-fold in 20 patients compared to 20 healthy men. In testing-phage, elevated levels of miR-21-5p,miR-30a-5p, miR-30d-5p, miR-103a-3p and miR-141-3p were further confirmed in 33 patients by comparing to 30 healthy men. In validation-phage, relieved pelvic-pain symptom of 21 follow-up patients was found to be accompanied by significant down-regulation of miR-21-5p, miR-103a-3p and miR-141-3p. Particularly, ROC curve analysis indicated the highest area under ROC curve (AUC) was found for miR-21-5p (0.891), followed in order by miR-141-3p and miR-103a-3p. Our studies provided evidence that secretory miRNAs existed in EPS and dysregulated EPS-miRNAs were associated with prostatitis. In particular, miR-21-5p possessed a high classify-accuracy for IIIA CP/CPPS patients with significant pelvic pain.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.